Titre : Inhibiteur tissulaire de métalloprotéinase-1

Inhibiteur tissulaire de métalloprotéinase-1 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Case-Control Studies
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Inhibiteur tissulaire de métalloprotéinase-1 : Questions médicales les plus fréquentes", "headline": "Inhibiteur tissulaire de métalloprotéinase-1 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Inhibiteur tissulaire de métalloprotéinase-1 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-08", "dateModified": "2025-04-03", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Inhibiteur tissulaire de métalloprotéinase-1" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Inhibiteur tissulaire des métalloprotéinases", "url": "https://questionsmedicales.fr/mesh/D019714", "about": { "@type": "MedicalCondition", "name": "Inhibiteur tissulaire des métalloprotéinases", "code": { "@type": "MedicalCode", "code": "D019714", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.815.875" } } }, "about": { "@type": "MedicalCondition", "name": "Inhibiteur tissulaire de métalloprotéinase-1", "alternateName": "Tissue Inhibitor of Metalloproteinase-1", "code": { "@type": "MedicalCode", "code": "D019715", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Anna Pryczynicz", "url": "https://questionsmedicales.fr/author/Anna%20Pryczynicz", "affiliation": { "@type": "Organization", "name": "Department of Pathomorphology, Medical University of Bialystok, Bialystok, Poland." } }, { "@type": "Person", "name": "Adina Elena Stanciu", "url": "https://questionsmedicales.fr/author/Adina%20Elena%20Stanciu", "affiliation": { "@type": "Organization", "name": "Department of Carcinogenesis and Molecular Biology, 'Prof. Dr. Alexandru Trestioreanu' Institute of Oncology, 022328 Bucharest, Romania." } }, { "@type": "Person", "name": "Adina Zamfir-Chiru-Anton", "url": "https://questionsmedicales.fr/author/Adina%20Zamfir-Chiru-Anton", "affiliation": { "@type": "Organization", "name": "ENT Department, 'Grigore Alexandrescu' Children's Emergency Hospital, 011743 Bucharest, Romania." } }, { "@type": "Person", "name": "Marcel Marian Stanciu", "url": "https://questionsmedicales.fr/author/Marcel%20Marian%20Stanciu", "affiliation": { "@type": "Organization", "name": "Electrical Engineering Faculty, 'Politehnica' University, 060042 Bucharest, Romania." } }, { "@type": "Person", "name": "Mirela Gherghe", "url": "https://questionsmedicales.fr/author/Mirela%20Gherghe", "affiliation": { "@type": "Organization", "name": "Department of Nuclear Medicine, 'Prof. Dr. Alexandru Trestioreanu' Institute of Oncology, 022328 Bucharest, Romania." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "A case-control study on immunologic markers of patients with vitiligo.", "datePublished": "2022-10-14", "url": "https://questionsmedicales.fr/article/36244264", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.biopha.2022.113785" } }, { "@type": "ScholarlyArticle", "name": "Case-Control Study of Long COVID, Sapporo, Japan.", "datePublished": "2023-04-12", "url": "https://questionsmedicales.fr/article/37044126", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3201/eid2905.221349" } }, { "@type": "ScholarlyArticle", "name": "Endothelium-biomarkers for postthrombotic syndrome: a case-control study.", "datePublished": "2023-03-29", "url": "https://questionsmedicales.fr/article/37016998", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/MBC.0000000000001192" } }, { "@type": "ScholarlyArticle", "name": "Risk Factors for Postoperative Pneumonia: A Case-Control Study.", "datePublished": "2022-07-08", "url": "https://questionsmedicales.fr/article/35875004", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fpubh.2022.913897" } }, { "@type": "ScholarlyArticle", "name": "Significance of temperature in antimuscarinic toxicity: a case-control study.", "datePublished": "2022-06-23", "url": "https://questionsmedicales.fr/article/35735006", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/15563650.2022.2088378" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines sécrétoires inhibitrices de protéinases", "item": "https://questionsmedicales.fr/mesh/D053491" }, { "@type": "ListItem", "position": 5, "name": "Inhibiteur tissulaire des métalloprotéinases", "item": "https://questionsmedicales.fr/mesh/D019714" }, { "@type": "ListItem", "position": 6, "name": "Inhibiteur tissulaire de métalloprotéinase-1", "item": "https://questionsmedicales.fr/mesh/D019715" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Inhibiteur tissulaire de métalloprotéinase-1 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Inhibiteur tissulaire de métalloprotéinase-1", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-06", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Inhibiteur tissulaire de métalloprotéinase-1", "description": "Comment diagnostiquer une anomalie de TIMP-1 ?\nQuels symptômes indiquent un déséquilibre de TIMP-1 ?\nY a-t-il des biomarqueurs associés à TIMP-1 ?\nQuel rôle joue TIMP-1 dans le cancer ?\nComment TIMP-1 est-il mesuré en clinique ?", "url": "https://questionsmedicales.fr/mesh/D019715?mesh_terms=Case-Control+Studies&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Inhibiteur tissulaire de métalloprotéinase-1", "description": "Quels symptômes sont liés à une surproduction de TIMP-1 ?\nTIMP-1 affecte-t-il la cicatrisation des plaies ?\nQuels signes indiquent une carence en TIMP-1 ?\nY a-t-il des symptômes associés à des maladies inflammatoires ?\nComment TIMP-1 influence-t-il l'inflammation ?", "url": "https://questionsmedicales.fr/mesh/D019715?mesh_terms=Case-Control+Studies&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Inhibiteur tissulaire de métalloprotéinase-1", "description": "Peut-on prévenir les déséquilibres de TIMP-1 ?\nQuels facteurs de mode de vie influencent TIMP-1 ?\nY a-t-il des recommandations pour maintenir TIMP-1 ?\nLes suppléments peuvent-ils aider TIMP-1 ?\nComment le suivi médical aide-t-il TIMP-1 ?", "url": "https://questionsmedicales.fr/mesh/D019715?mesh_terms=Case-Control+Studies&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Inhibiteur tissulaire de métalloprotéinase-1", "description": "Quels traitements ciblent TIMP-1 ?\nTIMP-1 peut-il être utilisé comme cible thérapeutique ?\nQuels médicaments influencent TIMP-1 ?\nY a-t-il des essais cliniques sur TIMP-1 ?\nComment les traitements affectent-ils TIMP-1 ?", "url": "https://questionsmedicales.fr/mesh/D019715?mesh_terms=Case-Control+Studies&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Inhibiteur tissulaire de métalloprotéinase-1", "description": "Quelles complications peuvent survenir avec un excès de TIMP-1 ?\nTIMP-1 est-il lié à des maladies chroniques ?\nComment TIMP-1 affecte-t-il la santé cardiovasculaire ?\nY a-t-il des risques de cancer liés à TIMP-1 ?\nQuels effets secondaires peuvent résulter d'un traitement de TIMP-1 ?", "url": "https://questionsmedicales.fr/mesh/D019715?mesh_terms=Case-Control+Studies&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Inhibiteur tissulaire de métalloprotéinase-1", "description": "Quels facteurs augmentent le risque de déséquilibre de TIMP-1 ?\nLes maladies auto-immunes influencent-elles TIMP-1 ?\nLe stress a-t-il un impact sur TIMP-1 ?\nL'alimentation joue-t-elle un rôle dans TIMP-1 ?\nY a-t-il un lien entre TIMP-1 et l'inactivité physique ?", "url": "https://questionsmedicales.fr/mesh/D019715?mesh_terms=Case-Control+Studies&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une anomalie de TIMP-1 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins mesurant les niveaux de TIMP-1 peuvent être effectués." } }, { "@type": "Question", "name": "Quels symptômes indiquent un déséquilibre de TIMP-1 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme l'inflammation ou des troubles de cicatrisation peuvent survenir." } }, { "@type": "Question", "name": "Y a-t-il des biomarqueurs associés à TIMP-1 ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des biomarqueurs comme le collagène et les métalloprotéinases sont souvent étudiés." } }, { "@type": "Question", "name": "Quel rôle joue TIMP-1 dans le cancer ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "TIMP-1 peut inhiber la progression tumorale en régulant la dégradation de la matrice." } }, { "@type": "Question", "name": "Comment TIMP-1 est-il mesuré en clinique ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Il est mesuré par des tests immunologiques spécifiques dans des échantillons de sang." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une surproduction de TIMP-1 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Une surproduction peut entraîner des douleurs articulaires et une fibrose tissulaire." } }, { "@type": "Question", "name": "TIMP-1 affecte-t-il la cicatrisation des plaies ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un excès de TIMP-1 peut ralentir la cicatrisation des plaies." } }, { "@type": "Question", "name": "Quels signes indiquent une carence en TIMP-1 ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Une carence peut se manifester par une dégradation excessive de la matrice extracellulaire." } }, { "@type": "Question", "name": "Y a-t-il des symptômes associés à des maladies inflammatoires ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des maladies comme l'arthrite peuvent être liées à des niveaux anormaux de TIMP-1." } }, { "@type": "Question", "name": "Comment TIMP-1 influence-t-il l'inflammation ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "TIMP-1 peut moduler l'inflammation en régulant les métalloprotéinases impliquées." } }, { "@type": "Question", "name": "Peut-on prévenir les déséquilibres de TIMP-1 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et un mode de vie sain peuvent aider à maintenir l'équilibre." } }, { "@type": "Question", "name": "Quels facteurs de mode de vie influencent TIMP-1 ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Le tabagisme et l'obésité peuvent affecter les niveaux de TIMP-1." } }, { "@type": "Question", "name": "Y a-t-il des recommandations pour maintenir TIMP-1 ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Pratiquer une activité physique régulière et gérer le stress sont recommandés." } }, { "@type": "Question", "name": "Les suppléments peuvent-ils aider TIMP-1 ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Certains suppléments antioxydants peuvent soutenir la régulation de TIMP-1." } }, { "@type": "Question", "name": "Comment le suivi médical aide-t-il TIMP-1 ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Un suivi régulier permet de détecter et de corriger les déséquilibres de TIMP-1." } }, { "@type": "Question", "name": "Quels traitements ciblent TIMP-1 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies géniques et des inhibiteurs spécifiques sont en cours d'étude." } }, { "@type": "Question", "name": "TIMP-1 peut-il être utilisé comme cible thérapeutique ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, en régulant TIMP-1, on peut potentiellement traiter certaines pathologies." } }, { "@type": "Question", "name": "Quels médicaments influencent TIMP-1 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Certains anti-inflammatoires peuvent moduler l'expression de TIMP-1." } }, { "@type": "Question", "name": "Y a-t-il des essais cliniques sur TIMP-1 ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, plusieurs essais cliniques explorent son rôle dans diverses maladies." } }, { "@type": "Question", "name": "Comment les traitements affectent-ils TIMP-1 ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements peuvent soit augmenter, soit diminuer les niveaux de TIMP-1 selon le contexte." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec un excès de TIMP-1 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Un excès peut entraîner des maladies fibrosantes et des troubles cardiovasculaires." } }, { "@type": "Question", "name": "TIMP-1 est-il lié à des maladies chroniques ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des niveaux anormaux de TIMP-1 sont associés à des maladies chroniques comme le diabète." } }, { "@type": "Question", "name": "Comment TIMP-1 affecte-t-il la santé cardiovasculaire ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux élevés de TIMP-1 peuvent contribuer à l'athérosclérose." } }, { "@type": "Question", "name": "Y a-t-il des risques de cancer liés à TIMP-1 ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux élevés de TIMP-1 peuvent être associés à une progression tumorale." } }, { "@type": "Question", "name": "Quels effets secondaires peuvent résulter d'un traitement de TIMP-1 ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements peuvent entraîner des effets secondaires comme des réactions allergiques." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque de déséquilibre de TIMP-1 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "L'âge avancé, le tabagisme et l'obésité sont des facteurs de risque connus." } }, { "@type": "Question", "name": "Les maladies auto-immunes influencent-elles TIMP-1 ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les maladies auto-immunes peuvent perturber l'équilibre de TIMP-1." } }, { "@type": "Question", "name": "Le stress a-t-il un impact sur TIMP-1 ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut affecter les niveaux de TIMP-1 dans l'organisme." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle dans TIMP-1 ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation riche en graisses saturées peut perturber les niveaux de TIMP-1." } }, { "@type": "Question", "name": "Y a-t-il un lien entre TIMP-1 et l'inactivité physique ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'inactivité physique peut contribuer à des déséquilibres de TIMP-1." } } ] } ] }

Sources (10000 au total)

Endothelium-biomarkers for postthrombotic syndrome: a case-control study.

The postthrombotic syndrome (PTS) is a long-term complication of deep venous thrombosis (DVT). Increase knowledge on the PTS pathophysiology and novel biomarkers are needed in order to predict PTS dev... A case-control study was conducted. Inclusion criteria were symptomatic and confirmed DVT patients treated with anticoagulants for at least 3 months. Villalta score was performed at the time of inclus... Thirty two patients and 61 controls were included. PTS patients showed higher levels of CEC (0.56/μl (0.34-1.5) vs. 0.20/μl (0.11-0.77); P = 0.04) and EPC (0.75/μl (0.38-1.52) vs. 0.09/μl (0.05-0.82);... The formation and early resolution of DVT are characterized by inflammation and endothelial/platelet activation. We have identified possible novel biomarkers such as CEC, EPC and fractalkine for the d...

Risk Factors for Postoperative Pneumonia: A Case-Control Study.

Postoperative pneumonia is a preventable complication associated with adverse outcomes, that greatly aggravates the medical expenses of patients. The goal of our study is to identify risk factors and ... A matched 1:1 case-control study, including adult patients who underwent surgery between January 2020 and June 2020, was conducted in the Second Affiliated Hospital of Kunming Medical University in Ch... Out of 17,190 surgical patients, 264 (1.54%) experienced postoperative pneumonia. Increased age, chronic obstructive pulmonary disease, emergency surgery, postoperative reduced albumin, prolonged vent... Postoperative pneumonia is associated with severe clinical outcomes. We identified six independent risk factors that can aid in risk stratification and management of patients at risk of postoperative ... www.chictr.org.cn, identifier: chiCTR2100045986....

Significance of temperature in antimuscarinic toxicity: a case-control study.

Antimuscarinic toxicity can result in temperature dysregulation, but the clinical significance of this is unclear. The objective of this study was to compare peak temperatures between antimuscarinic p... This was a case-control analysis at two large, urban, academic medical centers from January 1, 2016, through December 31, 2021. We compared peak temperature (... Fifty-six patients met inclusion criteria of which 23 developed severe outcomes: 16 seizures, 9 cases with hypotension, 5 intubations, and 2 ventricular dysrhythmias. Tmax amongst all patients ranged ... Maximum temperatures did not differ between patients with and without severe outcomes in the setting of antimuscarinic toxicity, and temperature was poorly predictive of outcomes. Our findings suggest...

A postmortem case control study of asbestos burden in lungs of malignant mesothelioma cases.

Asbestos lung content is regarded as the most reliable tool for causal attribution of malignant mesothelioma (MM) to previous asbestos exposures. However, there is a lack of studies on asbestos burden... Asbestos lung content has been assessed on formalin-fixed lung fragments using scanning electron microscopy coupled with energy dispersion spectroscopy (SEM-EDS) on individuals deceased from MM (cases... Asbestos and asbestos bodies (ABs) were found, respectively, in 73.7% and 43.2% of cases and in 28 and 22% of controls; in MM cases the most represented asbestos types were crocidolite and amosite, wh... The results suggest a correlation between asbestos burden in lungs and MM risk. The different concentration of chrysotile, as well as the different width of asbestos fibers in MM males and females mig...

Anemia and Idiopathic Intracranial Hypertension: A Case-Control Study.

Idiopathic intracranial hypertension (IIH) is a condition that mostly affects obese women of childbearing age but has been reported to be temporally related to new diagnoses of anemia. Despite these r... Consecutive IIH patients were recruited from neuro-ophthalmology clinics and matched by age and sex to consecutive patients attending neuro-ophthalmology clinics with diagnoses other than IIH. Complet... One hundred twenty-three IIH patients and 113 controls were included in the study. More IIH patients than controls had anemia (22.8%, 28/123 vs 10.6%, 12/113, P = 0.01) with an odds ratio of 2.48 (95%... Idiopathic intracranial hypertension patients have a higher prevalence of anemia compared with non-IIH neuro-ophthalmology patients. The anemia was mostly mild and may be explained by other factors re...

Study on the association between adverse drug reactions to opioids and gene polymorphisms: a case-case-control study.

Adverse drug reactions (ADRs) caused by opioid drugs show individual differences. Our objective was to explore the association between gene polymorphism and ADRs induced by opioid drugs.... Evidence-based medical data analysis was conducted for genes related to ADRs induced by opioid drugs to select target genes. Sixty patients with cancer pain who had ADRs after taking opioid drugs (mor... Based on a database search and evidence-based medical data, we identified CYP2D6*10, CYP3A5*3, ABCB1, and OPRM1 as target genes for detection. The results of statistical analysis showed no significant... Polymorphism of ABCB1 (062rs1045642) is related to ADRs caused by oxycodone, and the incidence of ADRs is higher with the allele T. Polymorphism of ABCB1 is expected to become a clinical predictor of ...

Systemic hormone therapy and dementia: A nested case-control and co-twin control study.

The effect of systemic hormone therapy (HT) on dementia risk is unclear. Our aim was to investigate the association between HT and dementia.... This register-based study consists of a nested case-control study and a co-twin control design, which controls for familial confounding, including shared genetics.... Through Danish national registries from 1995 to 2011, we identified: a) 2700 female singletons with incident dementia and 13,492 matched controls; b) 288 female twins with incident dementia and co-twi... The odds ratio (OR) for the association between systemic HT and dementia was 1.05, 95% CI = [0.93-1.19] in singletons and 2.10, 95% CI = [0.99-4.46] in twins. A statistically significant association w... Using Danish nationwide registries and controlling for education and for familial factors in a subsample, systemic HT was found to be associated with increased dementia risk if used before 2003, when ...